Jericho, New York, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the closing of its initial public offering (the âOfferingâ) of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses. The Offering was conducted on a firm commitment basis. The Companyâs shares of common stock began trading on the Nasdaq Capital Market on August 26, 2025 under the ticker symbol "CURX."
Related Questions
How will the $4.00 IPO price affect CURX's postâIPO market liquidity and price support?
What are the intended uses of the $15âŻmillion net proceeds and how will they impact future cashâburn and milestones?
How does CURX's valuation and share dilution compare to other earlyâstage botanicalâdrug companies that have recently gone public?